Two Sigma Investments’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Two Sigma Investments’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-63,181	Closed	-$250K	–	3634
2018 Q4	$250K	Buy	63,181 +51,301	+432%	+$656K	﹤0.01%	2583
2018 Q3	$235K	Buy	+11,880	New	+$300K	﹤0.01%	2915
2018 Q1	–	Sell	-2,970	Closed	-$235K	–	3715
2017 Q4	$235K	Buy	+2,970	New	+$220K	﹤0.01%	2848

Other funds holding MLNT

Isthmus Partners Madison, Wisconsin $953M AUM 18.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ZIM

Zacks Investment Management Chicago, Illinois $12.5B AUM 29.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments's MLNT Position: Q1 2019 in Review

Two Sigma Investments sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2019, closing a stake of 63,181 shares — an estimated $250K sold.

Two Sigma Investments first reported a position in MLNT in Q4 2017 and held it in 3 quarters. The position peaked at $250K in Q4 2018. 52 funds tracked by Wall St. Rank hold MLNT as of Q1 2019.

Two Sigma Investments reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Two Sigma Investments sold 63,181 Melinta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $250K.
Two Sigma Investments first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 3 quarters.
Two Sigma Investments's Melinta Therapeutics, Inc. Common Stock position peaked at $250K in Q4 2018.
52 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Two Sigma Investments's 13F filing for Q1 2019, filed 15 May 2019.